-DOCSTART-	O

Title	O
:	O
Selegiline	B-I
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
long	O
-	O
term	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
.	O

Czech	O
and	O
Slovak	O
Senile	O
Dementia	O
of	O
Alzheimer	O
Type	O
Study	O
Group	O
.	O

METHODS	O
:	O
Long	O
-	O
term	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Seven	O
cities	O
(	O
1	O
or	O
2	O
nursing	O
homes	O
in	O
each	O
city	O
)	O
in	O
the	O
Czech	O
and	O
Slovak	O
Republics	O
.	O

A	B-P
total	I-P
of	I-P
173	I-P
nursing	I-P
-	I-P
home	I-P
residents	I-P
fulfilling	I-P
the	I-P
DSM	I-P
-	I-P
III	I-P
criteria	I-P
for	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Selegiline	B-I
(	O
10	O
mg	O
per	O
day	O
)	O
or	O
placebo	B-C
(	O
both	O
including	O
50	O
mg	O
ascorbic	O
acid	O
)	O
administered	O
for	O
24	O
weeks	O
.	O

Clinical	B-O
Global	I-O
Impressions	I-O
scale	I-O
and	O
Nurses	B-O
Observation	I-O
Scale	I-O
for	I-O
Inpatient	I-O
Evaluation	I-O
at	O
baseline	O
and	O
at	O
weeks	O
6	O
,	O
12	O
and	O
24	O
;	O
Clock	B-O
Drawing	I-O
Test	I-O
at	O
baseline	O
and	O
24	O
weeks	O
,	O
results	O
of	O
which	O
were	O
evaluated	O
as	O
normal	O
or	O
pathologic	O
,	O
and	O
quantitatively	O
on	O
a	O
modified	O
6	O
-	O
point	O
scale	O
;	O
Sternberg	B-O
'	I-O
s	I-O
Memory	I-O
Scanning	I-O
test	I-O
at	O
baseline	O
and	O
at	O
weeks	O
6	O
,	O
12	O
and	O
24	O
;	O
Mini	B-O
Mental	I-O
State	I-O
Examination	I-O
,	O
and	O
electroencephalogram	B-O
at	O
baseline	O
and	O
24	O
weeks	O
;	O
Structured	B-O
Adverse	I-O
Effects	I-O
Rating	I-O
Scale	I-O
;	O
physical	B-O
,	O
laboratory	B-O
,	O
hematological	B-O

and	O
electrocardiographic	B-O
examinations	I-O
at	O
baseline	O
and	O
weeks	O
12	O
and	O
24	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
diclofenac	B-I
/	O
misoprostol	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
The	O
efficacy	O
and	O
safety	O
of	O
diclofenac	B-I
in	O
combination	O
with	O
misoprostol	B-I
(	O
D	B-I
/	O
M	B-I
)	O
was	O
evaluated	O
in	O
41	B-P
patients	I-P
with	I-P
mild	I-P
-	I-P
moderate	I-P
AD	I-P
in	I-P
a	I-P
prospective	I-P
25	I-P
-	I-P
week	I-P
,	I-P
randomized	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
placebo	I-P
-	I-P
controlled	I-P
trial	I-P
.	O

Efficacy	O
measures	O
comprised	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
and	O
noncognitive	B-O
subsections	I-O
,	O
Global	B-O
Deterioration	I-O
Scale	I-O
,	O
Clinical	B-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
,	O
Physical	B-O
Self	I-O
-	I-O
Maintenance	I-O
Scale	I-O
,	O
and	O
a	B-O
caregiver	I-O
-	I-O
rated	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
therapy	I-I
in	O
clinical	O
practice	O
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
Two	O
-	O
center	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
masked	O
crossover	O
study	O
.	O

Memory	O
disorders	O
units	O
at	O
Massachusetts	O
General	O
and	O
Brigham	O
and	O
Women	O
'	O
s	O
hospitals	O
,	O
Boston	O
.	O

Sixty	B-P
individuals	I-P
(	I-P
30	I-P
men	I-P
and	I-P
30	I-P
women	I-P
;	I-P
mean	I-P
+	I-P
/	I-P
-	I-P
SD	I-P
age	I-P
,	I-P
75	I-P
.	I-P
0	I-P
+	I-P
/	I-P
-	I-P
9	I-P
.	I-P

5	I-P
years	I-P
)	I-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
and	I-P
scores	I-P
of	I-P
20	I-P
or	I-P
less	I-P
on	I-P
the	I-P
information	I-P
-	I-P
memory	I-P
-	I-P
concentration	I-P
subscale	I-P
of	I-P
the	I-P
Blessed	I-P
Dementia	I-P
Scale	I-P
.	O

Placebo	O
wash	O
-	O
in	O
,	O
followed	O
in	O
randomized	O
sequence	O
by	O
(	O
1	O
)	O
donepezil	B-I
hydrochloride	I-I
therapy	I-I
,	O
5	O
mg	O
/	O
d	O
,	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
placebo	O
washout	O
for	O
6	O
weeks	O
and	O
(	O
2	O
)	O
placebo	B-C
treatment	I-C
for	O
6	O
weeks	O
.	O

Change	O
in	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
scores	I-O
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
the	O
two	O
6	O
-	O
week	O
treatment	O
periods	O
.	O

-DOCSTART-	O

Title	O
:	O
Memantine	B-I
in	O
severe	O
dementia	O
:	O
results	O
of	O
the	O
9	O
M	O
-	O
Best	O
Study	O
(	O
Benefit	O
and	O
efficacy	O
in	O
severely	B-P
demented	I-P
patients	I-P
during	I-P
treatment	I-P
with	I-P
memantine	I-P
)	O
.	O

METHODS	O
:	O
Dementia	O
was	O
defined	O
by	O
DSM	O
-	O
III	O
-	O
R	O
criteria	O
and	O
severity	O
was	O
assessed	O
by	O
the	O
Global	O
Deterioration	O
Scale	O
(	O
stages	O
5	O
-	O
7	O
)	O
and	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
<	O
10	O
points	O
)	O
.	O

Primary	O
endpoints	O
were	O
the	B-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
rated	O
by	O
the	O
physician	O
,	O
and	O
the	B-O
Behavioural	I-O
Rating	I-O
Scale	I-O
for	I-O
Geriatric	I-O
Patients	I-O
(	I-O
BGP	I-O
)	I-O
,	I-O
subscore	I-O
'	I-O
care	I-O
dependence	I-O
'	I-O
,	O
rated	O
by	O
the	O
nursing	O
staff	O
.	O

Secondary	O
endpoints	O
included	O
the	B-O
modified	I-O
D	I-O
-	I-O
Scale	I-O
(	I-O
Arnold	I-O
/	I-O
Ferm	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
1	O
-	O
year	O
controlled	O
trial	O
of	O
acetyl	B-I
-	I-I
l	I-I
-	I-I
carnitine	I-I
in	O
early	O
-	O
onset	O
AD	O
.	O

METHODS	O
:	O
A	O
1	O
-	O
year	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
trial	O
was	O
conducted	O
.	O

Subjects	O
were	O
45	B-P
to	I-P
65	I-P
years	I-P
old	I-P
,	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
probable	I-P
AD	I-P
according	I-P
to	I-P
National	I-P
Institute	I-P
of	I-P
Neurological	I-P
Communicative	I-P
Disorders	I-P
-	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Related	I-P
Disorders	I-P
Association	I-P
criteria	I-P
and	I-P
had	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
between	I-P
12	I-P
and	I-P
26	I-P
.	O

They	O
were	O
treated	O
with	O
ALCAR	B-I
(	O
1	O
g	O
tid	O
)	O
or	O
placebo	B-C
.	O

Primary	O
outcome	O
measures	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Component	I-O
and	O
the	B-O
Clinical	I-O
Dementia	I-O
Rating	I-O
Scale	I-O
.	O

Secondary	O
measures	O
included	O
the	B-O
ADAS	I-O
Non	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
,	O
the	B-O
MMSE	I-O
,	O
an	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Scale	I-O
(	I-O
ADL	I-O
)	I-O
,	O
and	O
a	B-O
Clinician	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CIBIC	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
study	O
of	O
Cerebrolysin	B-I
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
A	O
4	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
clinical	O
trial	O
.	O

An	O
unequal	O
(	O
Cerebrolysin	B-I
:	O
placebo	B-C
=	O
2	O
:	O
1	O
)	O
randomization	O
was	O
used	O
to	O
assign	O
more	O
patients	O
to	O
the	O
treatment	O
group	O
.	O

University	O
medical	O
centers	O
and	O
community	O
geriatric	O
hospitals	O
in	O
Korea	O
.	O

Fifty	B-P
-	I-P
three	I-P
men	I-P
and	I-P
women	I-P
at	I-P
least	I-P
50	I-P
years	I-P
of	I-P
age	I-P
admitted	I-P
to	I-P
hospitals	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
otherwise	I-P
in	I-P
good	I-P
health	I-P
.	O

The	O
treatment	O
group	O
(	O
n	O
=	O
34	O
)	O
received	O
Cerebrolysin	B-I
(	O
30	B-I
mL	I-I
Cerebrolysin	I-I
in	O
100	O
mL	O
physiologic	O
saline	O
IV	O
)	O
once	O
a	O
day	O
from	O
Monday	O
to	O
Friday	O
for	O
4	O
weeks	O
.	O

The	O
control	O
group	O
(	O
n	O
=	O
19	O
)	O
received	O
placebo	B-C
.	O

Primary	O
outcome	O
measures	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
the	B-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Severity	I-O
/	I-O
Change	I-O
(	I-O
CGIS	I-O
/	I-O
C	I-O
)	I-O
.	O

Secondary	O
outcome	O
measures	O
included	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Geriatric	B-O
Depression	I-O
Scale	I-O
(	I-O
GDS	I-O
)	I-O
,	O
Katz	B-O
Index	I-O
of	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
ADL	I-O
)	I-O
,	O
and	O
Lawton	B-O
Instrumental	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
IADL	I-O
)	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
controlled	O
trial	O
of	O
a	O
home	O
environmental	O
intervention	O
:	O
effect	O
on	O
efficacy	O
and	O
upset	O
in	O
caregivers	B-P
and	O
on	O
daily	O
function	O
of	O
persons	B-P
with	I-P
dementia	I-P
.	O

METHODS	O
:	O
Families	B-P
(	I-P
N	I-P
=	I-P
171	I-P
)	I-P
of	I-P
dementia	I-P
patients	I-P
were	O
randomized	O
to	O
intervention	O
or	O
usual	B-C
care	I-C
control	I-C
group	O
.	O

The	O
intervention	O
involved	O
5	B-I
90	I-I
-	I-I
min	I-I
home	I-I
visits	I-I
by	O
occupational	O
therapists	O
who	O
provided	O
education	O
and	O
physical	O
and	O
social	O
environmental	O
modifications	O
.	O

-DOCSTART-	O

Title	O
:	O
Response	O
of	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
to	O
rivastigmine	B-I
treatment	I-I
is	O
predicted	O
by	O
the	O
rate	O
of	O
disease	O
progression	O
.	O

METHODS	O
:	O
A	O
26	O
-	O
week	O
,	O
open	O
-	O
label	O
extension	O
study	O
following	O
a	O
26	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Outpatient	O
research	O
centers	O
at	O
22	O
sites	O
in	O
the	O
United	O
States	O
.	O

We	O
studied	O
187	B-P
of	I-P
235	I-P
patients	I-P
originally	O
randomized	O
to	O
receive	O
placebo	B-C
treatment	I-C
in	O
the	O
double	O
-	O
blind	O
phase	O
of	O
the	O
trial	O
who	O
continued	O
with	O
open	O
-	O
label	O
(	O
rivastigmine	B-I
)	O
extension	O
therapy	O
.	O

Placebo	B-C
treatment	I-C
for	O
26	O
weeks	O
followed	O
by	O
rivastigmine	B-I
treatment	I-I
,	O
2	O
to	O
12	O
mg	O
/	O
d	O
,	O
for	O
26	O
weeks	O
.	O

Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
Progressive	B-O
Deterioration	I-O
Scale	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
and	O
Global	B-O
Deterioration	I-O
Scale	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
donepezil	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
in	I-P
the	I-P
nursing	I-P
home	I-P
setting	I-P
.	O

METHODS	O
:	O
Twenty	O
-	O
four	O
-	O
week	O
,	O
randomized	O
,	O
multicenter	O
,	O
parallel	O
-	O
group	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Twenty	O
-	O
seven	O
nursing	O
homes	O
across	O
the	O
United	O
States	O
.	O

Two	B-P
hundred	I-P
eight	I-P
nursing	I-P
home	I-P
patients	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
probable	I-P
or	I-P
possible	I-P
AD	I-P
,	I-P
or	I-P
AD	I-P
with	I-P
cerebrovascular	I-P
disease	I-P
;	I-P
mean	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
14	I-P
.	I-P
4	I-P
;	I-P
mean	I-P
age	I-P
85	I-P
.	I-P
7	I-P
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
-	I-O
Nursing	I-O
Home	I-O
Version	I-O
(	I-O
NPI	I-O
-	I-O
NH	I-O
)	I-O
.	O

Secondary	O
efficacy	O
measures	O
were	O
the	B-O
Clinical	I-O
Dementia	I-O
Rating	I-O
(	I-O
Nursing	I-O
Home	I-O
Version	I-O
)	I-O
-	I-O
Sum	I-O
of	I-O
the	I-O
Boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
,	O
MMSE	B-O
,	O
and	O
the	B-O
Physical	I-O
Self	I-O
-	I-O
Maintenance	I-O
Scale	I-O
(	I-O
PSMS	I-O
)	I-O
.	O

Safety	O
was	O
monitored	O
by	O
physical	B-O
examinations	I-O
,	O
vital	B-O
signs	I-O
,	O
clinical	B-O
laboratory	I-O
tests	I-O
,	O
electrocardiograms	B-O
(	I-O
ECGs	I-O
)	I-O
,	O
and	O
treatment	B-O
-	I-O
emergent	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Does	O
behavioral	O
improvement	O
with	O
haloperidol	B-I
or	O
trazodone	B-I
treatment	I-I
depend	O
on	O
psychosis	O
or	O
mood	O
symptoms	O
in	O
patients	B-P
with	I-P
dementia	I-P
?	O
.	O

METHODS	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
9	O
-	O
week	O
treatment	O
trial	O
.	O

Inpatient	O
geropsychiatry	O
unit	O
.	O

Twenty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
dementia	I-P
and	I-P
agitated	I-P
or	I-P
aggressive	I-P
behaviors	I-P
.	O

Haloperidol	B-I
1	O
to	O
5	O
mg	O
/	O
day	O
or	O
trazodone	B-I
50	O
to	O
250	O
mg	O
/	O
day	O
.	O

Cohen	B-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
(	I-O
CMAI	I-O
)	I-O
,	O
Hamilton	B-O
Depression	I-O
Rating	I-O
Scale	I-O
(	I-O
Ham	I-O
-	I-O
D	I-O
)	I-O
,	O
and	O
delusional	B-O
thoughts	I-O
subscale	I-O
and	O
hallucinations	B-O
subscale	I-O
of	I-O
the	I-O
Behavioral	I-O
Pathology	I-O
in	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Rating	I-O
Scale	I-O
(	I-O
BEHAVE	I-O
-	I-O
AD	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
24	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
donepezil	B-I
in	O
patients	B-P
with	I-P
Down	I-P
syndrome	I-P
and	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
-	O
-	O
pilot	O
study	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
24	O
-	O
week	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
placebo	B-C
or	O
donepezil	B-I
(	O
5	O
mg	O
per	O
day	O
during	O
the	O
first	O
four	O
weeks	O
,	O
and	O
then	O
10	O
mg	O
per	O
day	O
thereafter	O
)	O
.	O

Primary	O
efficacy	O
was	O
measured	O
using	O
the	B-O
Dementia	I-O
Scale	I-O
for	I-O
Mentally	I-O
Retarded	I-O
Persons	I-O
(	I-O
DMR	I-O
)	I-O
,	O
and	O
secondary	O
efficacy	O
was	O
measured	O
using	O
the	B-O
Severe	I-O
Impairment	I-O
Battery	I-O
(	I-O
SIB	I-O
)	I-O
,	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
and	O
by	O
the	B-O
Adaptive	I-O
Behavior	I-O
Scale	I-O
(	I-O
ABS	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
galantamine	B-I
in	O
probable	O
vascular	O
dementia	O
and	O
Alzheimer	O
'	O
s	O
disease	O
combined	O
with	O
cerebrovascular	O
disease	O
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
Eligible	O
patients	O
were	O
randomly	O
assigned	O
galantamine	B-I
24	O
mg	O
/	O
day	O
(	O
n=396	O
)	O
or	O
placebo	B-C
(	O
n=196	O
)	O
in	O
a	O
multicentre	O
,	O
double	O
-	O
blind	O
,	O
6	O
-	O
month	O
trial	O
.	O

Primary	O
endpoints	O
were	O
cognition	B-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
disease	I-O
assessment	I-O
scale	I-O
,	O
cognitive	B-O
subscale	I-O
[	I-O
ADAS	I-O
-	I-O
cog	I-O
]	I-O
)	O
and	O
global	B-O
functioning	I-O
(	O
clinician	B-O
'	I-O
s	I-O
interview	I-O
-	I-O
based	I-O
impression	I-O
of	I-O
change	I-O
plus	O
caregiver	B-O
input	I-O
[	I-O
CIBIC	I-O
-	I-O
plus	I-O
]	I-O
)	O
.	O

Secondary	O
endpoints	O
included	O
assessments	O
of	O
activities	B-O
of	I-O
daily	I-O
living	I-O
and	O
behavioural	B-O
symptoms	I-O
.	O

Patients	O
were	O
monitored	O
for	O
adverse	B-O
events	I-O
.	O

Analyses	O
were	O
on	O
the	O
basis	O
of	O
observed	O
case	O
or	O
last	O
observation	O
carried	O
forward	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
social	B-I
support	I-I
on	O
well	O
-	O
being	O
of	O
demented	B-P
nursing	I-P
home	I-P
residents	I-P
.	O

The	O
Kferberg	O
Visitation	O
Study	O
]	O
.	O

METHODS	O
:	O
A	O
field	O
experiment	O
with	O
slightly	B-P
to	I-P
seriously	I-P
demented	I-P
institutionalized	I-P
aged	I-P
persons	I-P
(	I-P
MMS	I-P
5	I-P
-	I-P
25	I-P
)	I-P
was	O
carried	O
out	O
to	O
assess	O
the	O
effect	O
of	O
increased	B-I
social	I-I
support	I-I
upon	O
their	O
well	O
-	O
being	O
.	O

Voluntary	O
helpers	O
,	O
who	O
were	O
willing	O
to	O
visit	O
their	O
patients	O
on	O
a	O
regular	O
basis	O
,	O
were	O
recruited	O
by	O
appeals	O
at	O
the	O
senior	O
university	O
and	O
by	O
advertisements	O
.	O

The	O
volunteers	O
were	O
trained	O
to	O
deal	O
with	O
the	O
demented	O
and	O
were	O
looked	O
after	O
regularly	O
.	O

The	O
test	O
subjects	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
test	O
groups	O
.	O

The	O
first	O
group	O
was	O
visited	O
regularly	O
for	O
ten	O
weeks	O
,	O
whereas	O
the	O
second	O
group	O
served	O
as	O
a	O
control	O
group	O
.	O

The	O
participants	O
of	O
the	O
experimental	O
group	O
received	O
a	O
visiting	O
card	O
with	O
a	O
photo	O
of	O
the	O
volunteer	O
and	O
the	O
next	O
appointment	O
date	O
to	O
remember	O
their	O
visitors	O
and	O
to	O
increase	O
the	O
effect	O
of	O
predictability	O
.	O

-DOCSTART-	O

Title	O
:	O
Cerebrolysin	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
with	O
a	O
neurotrophic	O
agent	O
.	O

Cerebrolysin	O
(	O
Cere	O
)	O
is	O
a	O
compound	O
with	O
neurotrophic	O
activity	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
in	O
earlier	O
trials	O
.	O

In	O
this	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
were	O
injected	O
intravenously	O
with	O
placebo	O
or	O
30	O
mL	O
Cere	O
five	O
days	O
per	O
week	O
for	O
four	O
weeks	O
.	O

Effects	O
on	O
cognition	O
and	O
global	O
function	O
were	O
evaluated	O
with	O
the	O
Alzheimer	O
Disease	O
Assessment	O
Scale	O
-	O
Cognitive	O
Subscale	O
(	O
ADAS	O
-	O
Cog	O
)	O
and	O
the	O
Clinicians	O
Interview	O
-	O
based	O
Impression	O
of	O
Change	O
with	O
Caregiver	O
Input	O
scale	O
(	O
CIBIC	O
+	O
)	O
4	O
,	O
12	O
,	O
24	O
weeks	O
after	O
the	O
beginning	O
of	O
the	O
injections	O
.	O

192	O
patients	O
were	O
enrolled	O
,	O
95	O
were	O
randomized	O
to	O
placebo	O
,	O
and	O
97	O
to	O
Cere	O
.	O

At	O
baseline	O
,	O
there	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
for	O
age	O
,	O
age	O
of	O
onset	O
of	O
dementia	O
,	O
and	O
the	O
number	O
of	O
patients	O
with	O
hallucinations	O
.	O

At	O
week	O
12	O
there	O
was	O
a	O
significant	O
difference	O
on	O
the	O
CIBIC	O
+	O
(	O
p	O
=	O
0	O
.	O
033	O
)	O
in	O
favor	O
of	O
Cere	O
.	O

The	O
number	O
of	O
CIBIC	O
+	O
responders	O
(	O
score	O
<	O
or	O
=	O
4	O
)	O
,	O
was	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
,	O
with	O
68	O
(	O
76	O
%	O
)	O
in	O
the	O
Cere	O
group	O
and	O
51	O
(	O
57	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O

Trends	O
were	O
noted	O
in	O
the	O
Disability	O
Assessment	O
in	O
Dementia	O
scale	O
and	O
the	O
Cornell	O
Depression	O
Scale	O
.	O

Adverse	O
events	O
were	O
recorded	O
in	O
73	O
%	O
of	O
placebo	O
and	O
64	O
%	O
of	O
Cere	O
patients	O
.	O

Most	O
common	O
adverse	O
events	O
were	O
headaches	O
,	O
dizziness	O
,	O
weight	O
loss	O
and	O
anxiety	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
improvement	O
in	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
dementia	O
after	O
treatment	O
with	O
the	B-I
acetylcholine	I-I
precursor	I-I
choline	I-I
alfoscerate	I-I
:	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
patients	B-P
affected	I-P
by	I-P
mild	I-P
to	I-P
moderate	I-P
dementia	I-P
of	I-P
the	I-P
Alzheimer	I-P
type	I-P
were	O
treated	O
with	O
CA	B-I
(	O
400	O
-	O
mg	O
capsules	O
)	O
or	O
placebo	B-C
capsules	I-C
,	O
3	O
times	O
daily	O
,	O
for	O
180	O
days	O
.	O

Efficacy	O
outcome	O
measures	O
that	O
were	O
assessed	O
at	O
the	O
beginning	O
of	O
the	O
investigation	O
and	O
after	O
90	O
and	O
180	O
days	O
of	O
treatment	O
included	O
scores	O
of	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
the	B-O
Global	I-O
Deterioration	I-O
Scale	I-O
(	I-O
GDS	I-O
)	I-O
,	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Behavioral	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Behav	I-O
)	I-O
,	O
all	B-O
items	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
-	I-O
Total	I-O
)	I-O
,	O
and	O
the	B-O
Clinical	I-O
Global	I-O
Impression	I-O
(	I-O
CGI	I-O
)	I-O
scale	I-O
.	O

The	B-O
Global	I-O
Improvement	I-O
Scale	I-O
(	I-O
GIS	I-O
)	I-O
score	I-O
was	O
assessed	O
after	O
90	O
and	O
180	O
days	O
of	O
treatment	O
.	O

